Jennifer Zachary's Insider Trades & SAST Disclosures
Jennifer Zachary's most recent trade in Merck & Co Inc was a trade of 25,423 Common Stock done at an average price of $97.9 . Disclosure was reported to the exchange on Jan. 27, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jennifer Zachary.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 97.94 per share. | 27 Jan 2025 | 25,423 | 55,285 (0%) | 0% | 97.9 | 2,489,929 | Common Stock |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 24,454 | 24,454 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 4,790 | 14,296 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 35,156 | 35,156 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 126.97 per share. | 02 Feb 2024 | 49,499 | 29,057 (0%) | 0% | 127.0 | 6,284,779 | Common Stock |
| Merck & Co Inc | Zachary Jennifer | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.10 per share. | 02 Feb 2024 | 19,417 | 78,556 (0%) | 0% | 87.1 | 1,691,221 | Common Stock |
| Merck & Co Inc | Zachary Jennifer | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 19,417 | 38,835 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Zachary Jennifer | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 119.43 per share. | 22 Jan 2024 | 23,298 | 59,139 (0%) | 0% | 119.4 | 2,782,480 | Common Stock |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 17,892 | 17,892 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 3,486 | 9,506 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 117.59 per share. | 04 May 2023 | 19,141 | 35,127 (0%) | 0% | 117.6 | 2,250,834 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 41,494 | 41,494 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 103.17 per share. | 03 Feb 2023 | 75,436 | 53,919 (0%) | 0% | 103.2 | 7,782,762 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2023 | 75,436 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.04 per share. | 03 Feb 2023 | 75,436 | 129,355 (0%) | 0% | 56.0 | 4,227,433 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 109.88 per share. | 23 Jan 2023 | 15,631 | 53,919 (0%) | 0% | 109.9 | 1,717,534 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 99.07 per share. | 28 Oct 2022 | 99,768 | 103,527 (0%) | 0% | 99.1 | 9,884,016 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 68,367 | 123,015 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 68,367 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 99.85 per share. | 28 Oct 2022 | 65,487 | 38,040 (0%) | 0% | 99.9 | 6,538,877 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 51,884 | 174,899 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 51,884 | 25,946 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 28,396 | 203,295 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2022 | 28,396 | 56,792 | - | - | Stock Option (Right to Buy) | |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 29,739 | 29,739 | - | - | Stock Option (Right to Buy) | |
| Regenxbio Inc | Jennifer Zachary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 6,020 | 6,020 (0%) | 0% | 0 | Common Stock | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2022 | 58,252 | 58,252 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 73.51 per share. | 24 Feb 2022 | 18,420 | 53,419 (0%) | 0% | 73.5 | 1,354,054 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2021 | 82,653 | 82,653 | - | - | Stock Option (Right to Buy) | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 75.98 per share. | 04 May 2021 | 5,772 | 36,983 (0%) | 0% | 76.0 | 438,557 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2021 | 5,772 | 0 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.98 per share. | 04 May 2021 | 2,843 | 34,140 (0%) | 0% | 76.0 | 216,011 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 72.62 per share. | 26 Feb 2021 | 24,199 | 30,947 (0%) | 0% | 72.6 | 1,757,331 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.67 per share. | 04 May 2020 | 5,772 | 9,489 (0%) | 0% | 77.7 | 448,311 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2020 | 5,772 | 5,772 | - | - | Restricted Stock Unit | |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.67 per share. | 04 May 2020 | 2,843 | 6,646 (0%) | 0% | 77.7 | 220,816 | Common Stock |
| Merck & Co Inc | Jennifer Zachary | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2020 | 75,514 | 75,514 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges